Nanobiotix
NBTX
4 hedge funds and large institutions have $12.4M invested in Nanobiotix in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
1% more capital invested
Capital invested by funds: $12.2M → $12.4M (+$159K)
0.01% less ownership
Funds ownership: 9.94% → 9.93% (-0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.07K |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
-$1.04K |
NBTX Hedge Fund Activity: Q1 2023 in Review
4 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Nanobiotix (NBTX) for Q1 2023, worth a combined $12.4M — up 1.3% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NBTX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, cutting an estimated $3.07K.
- 4 institutional investors held Nanobiotix (NBTX) as of Q1 2023, down from 5 in Q4 2022.
- Funds reported $12.4M of Nanobiotix stock for Q1 2023, up 1.3% quarter-over-quarter.
- 0 funds opened new Nanobiotix positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Nanobiotix seller in Q1 2023 was UBS Group, an estimated $3.07K sold.
Based on aggregated 13F filings for Q1 2023.